Circulating Tumor DNA
Recruiting now · Phase 2
Conditions studied: ER+ Breast Cancer
In brief
This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in three separate phases: screening, treatment, and follow-up.
Key facts
- Study ID
- NCT06923527
- Run by
- Yale University
- People needed
- 50
- Starts
- 2025-09-30
- Expected to finish
- 2027-09-01
- Last updated by the study team
- 2026-06-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center — Washington D.C., District of Columbia, United States (enrolling)
- Montefiore Einstein Comprehensive Cancer Center — The Bronx, New York, United States (enrolling)
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Yale University — New Haven, Connecticut, United States (enrolling)
- Sidney Kimmel Comprehensive Cancer Center at John Hopkins — Baltimore, Maryland, United States
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.